NAD+ Cellular Energy Production

Until Now stable NAD+ has only been available in IV drip therapy clinics, due to the fragility of the molecule. Using clinically proven high-stability liposomes, as a delivery mechanism HINNAO NAD+ absorbs instantly via the mucous membrane crossing the blood brain barrier.

Low NAD+ levels are associated with ageing and being more prone to chronic diseases such as diabetes, heart disease, Alzheimer’s disease and vision loss.

Our patented HINNAO technology stabilises each lipid particle, encapsulating the active ingredient within a phospholipid-based MCT carrier system, protecting it from oxidation. This formulation is designed for rapid absorption through the mucous membrane, allowing the active ingredient to bypass first-pass metabolism in the liver and avoid degradation in the stomach.

Independent third-party testing using a Franz Cell Diffusion Study (mucous membrane) demonstrated an average absorption of 72% within 60 seconds, increasing to 82% within 90 seconds across multiple active ingredients, including Vitamin D, Glutathione, and B12. This confirms the high efficiency of our delivery system, providing near-instant bioavailability compared to traditional oral administration, which undergoes slower gastrointestinal processing.

MCT Oil (Medium Chain Triglycerides) [Derived from Coconut oil], NAD+ (Nicotinamide Adenine Dinucleotide) (Oxidized Form), Sweetener: Raw Steviol Glycosides, Natural Island Punch Flavourings: (Cold Pressed Orange Oils [Valencia and Californian], Distilled Lime Oil, Cold Pressed Lemon Oil)